Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DF32PZ
|
|||
| Drug Name |
JNJ-78934804
|
|||
| Indication | Ulcerative colitis [ICD-11: DD71; ICD-9: 556] | Phase 2 | [1] | |
| Company |
Janssen Research & Development Raritan, NJ
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05242484) A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.